Safety trials under way for GSK and Canadian Public Health Agency's Ebola vaccines

27 October 2014

Safety trials are currently under way in two of the most advanced Ebola candidates, and the World Health Organization has suggested that around 200,000 doses could be ready for use in West Africa within the first half of 2015.

One of the drugs is being developed by UK pharma major GlaxoSmithKline (LSE: GSK) in partnership with the US National Institutes of Health, and the other is being developed by the Canadian Public Health Agency, and is licensed to NewLink genetics. The safety studies are taking place in the US, the UK and Mali at present.

NewLink’s vaccine VSV-EBOV recently received clearance from the FDA to enter early-stage studies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK